Industry to blame for heterogeneity in glucosamine trials?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1601, 2007-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic evaluations alongside phase III trials?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 424, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Is the use of placebos justified in advanced cancer trials?

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Is animal testing a beneficial prelude to clinical trials?

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Concentration-Controlled or Effect-Controlled Trials: Useful Alternatives to Conventional Dose-Controlled Trials?

By Grahnén A.

Clinical Pharmacokinetics, Vol. 40, Iss. 5, 2001-01 ,pp. : 317-325

Adis International

Access to resources Recommend Favorite

What can be done to improve patient safety in phase I trials?

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite